Physcian's name and phone number 
Institution's name 
Patient's name and hospital unit number 
Patient's date of birth, sex, race, height and weight 
Previous treatment (surgery, radiation therapy, chemotherapy) with dates 
(must be > 6 weeks from enrollment or patient's tumor must be 
progressing such that waiting 6 weeks is inadvisable) 
Date and results of the following tests; 
hemoglobin (must be > 9.9 mg/dL)) 
platelet count (must be > 124,000/mm^) 
BUN (must be < 30mg/dl) 
creatinine (must be < 2m^dl) 
alkaline phosphatase, SGrOT (must be < 2x normal upper limit) 
amylase, lipase (must be < 1.5x normal upper limit) 
4.22 The registrar will review the eligibilty checklist to verify patient eligibility. If the patient 
meets all criteria, the patient will be registered onto this study. 
4.23 The registrar will remind the person registering the new patient of the expectations 
concerning submission of data and laboratory specimens. 
5.0 Therapeutic Modalities 
5.1 Preparation and Characterization of Biological Agents 
5.11 Genetically Modified Tumor Cells 
Tumor samples will be obtained from clinically indicated procedures under sterile conditions. The tumor 
tissue will be minced and placed in Richter's zinc option media to establish growth of tumor cells in 
culture. For some patients, the cultured cells will be genetically modified by retroviral mediated gene 
transfer to express the IL-2 gene product. Other patients will be treated with an HLA A2 positive 
allogeneic glioblastoma cell line transduced with the same IL-2 retroviral vector. All tissue processing 
procedures will be approved by the FDA. 
5.12 Retroviral Vectors 
The retroviral vector utilized in this study is derived from a murine retrovirus similar to the vectors 
employed by a number of investigators for in vitro and in vivo studies including recently approved 
investigations with human subjects (14). The cytokine vector used in this investigation (GlNaCvi2.23) 
was developed by investigators at Genetic Therapy Incorporated. This vector contains human IL-2 cDNA 
under the control of an internal CMV promoter. 
Before utilization in human studies, the transduced cells will be certified to be free of contaminating 
replication competent retrovirus and other adventitious agents by criteria recommended by the FDA. The 
minimum assays to be performed will include the following: 
Sterility testing by bacterial and fungal culture 
Mycoplasma testing by Gen-Probe lot assay 
Replication competent viral testing by feline PG-4 S+L- Assay 
Recombinant DNA Research, Volume 19 
[625] 
